Table 2.

Case summaries.

Case	Age/Sex	Prior BCMA CAR T?	Prior GPRC5D CAR T?	Neurologic Toxicities	Initial dosing* schedule	Dosing* modification	Resolution?
1	65 F	Yes	No	Dizziness, fall	0.8 Q2W	DC	Improved
2	50 M	Yes	No	Dizziness, diplopia, tremors, restlessness, CN 6 palsy	0.8 Q2W	DC	Improved
3	67 F	Yes	Yes	Dizziness, dyskinesia, + Rhomberg	0.8 Q2W	Held for 2 months followed by 0.4 Q2W	Resolved
4	45 M	Yes	No	Diplopia, dizziness, truncal ataxia	0.8 Q2W	Held for 2 months followed by 0.6 Q4W.	Resolution with DC and recurrence after each dose.

^*Doses are in mg/kg units.

F female, M male, BCMA B-cell maturation antigen, CAR T chimeric antigen receptor T cell therapy, GPRC5D G-protein-coupled receptor class 5 member D, Q2W every two weeks, QW every week, DC discontinued, CN cranial nerve.